MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Array Biopharma Company Profile (NASDAQ:ARRY)

Consensus Ratings for Array Biopharma (NASDAQ:ARRY) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.25 (139.13% upside)

Analysts' Ratings History for Array Biopharma (NASDAQ:ARRY)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016SunTrustInitiated CoverageBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016Stifel NicolausLower Price TargetBuy$8.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2015JPMorgan Chase & Co.Boost Price TargetOverweight$8.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Array Biopharma (NASDAQ:ARRY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2016        
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2015Q215($0.18)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Array Biopharma (NASDAQ:ARRY)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.18)($0.15)($0.16)
Q2 20163($0.18)($0.14)($0.16)
Q4 20163($0.27)$0.09($0.13)
Q1 20171($0.20)($0.20)($0.20)
Q2 20171($0.21)($0.21)($0.21)
Q3 20171($0.24)($0.24)($0.24)
Q4 20171($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)
Dividend History for Array Biopharma (NASDAQ:ARRY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Array Biopharma (NASDAQ:ARRY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Array Biopharma (NASDAQ:ARRY)
DateHeadline
06/25/16 02:34 PMArray Biopharma Incorporated (NASDAQ:ARRY) Shorted Shares Increased 9.44% After Market Selling - Engelwood Daily
06/24/16 08:25 AMArray BioPharma Inc. (ARRY) Updated Price Targets - FTSE News
06/24/16 08:25 AMIs Buying Array Biopharma Inc Here a Winning Strategy? - Engelwood Daily
06/24/16 08:25 AMCovering the Bases on Array BioPharma Inc. (NASDAQ:ARRY): Where is the Stock Going? - Press Telegraph
06/24/16 08:25 AMArray BioPharma Inc. (ARRY) Jumps 7.51% on June 23 - Equities.com
06/22/16 07:22 AMBrokers Issue Average Price Target Of 7.66 On Array BioPharma Inc. (ARRY) - Fiscal Standard
06/22/16 07:22 AMArray BioPharma (NASDAQ:ARRY) Analyst Rating Consensus - TheFounders Daily
06/21/16 07:22 AMAnalysts and Technical Insights on Array BioPharma Inc (NASDAQ:ARRY) - Street Report
06/19/16 07:18 AMArray BioPharma Inc. (ARRY) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 10:52 AMArray BioPharma, Inc. – Value Analysis (NASDAQ:ARRY) : June 17, 2016 -
06/16/16 02:34 PMAnalyst Overview: Array BioPharma Inc. (NASDAQ:ARRY) - News Oracle
06/16/16 02:34 PMTrading Overview of Two Stocks: Array BioPharma Inc. (NASDAQ:ARRY) , Quintiles Transitional Holdings Inc. (NYSE:Q) - Street Updates
06/16/16 02:34 PMAnalyst Recommendations: The Allstate Corporation (NYSE:ALL), Array BioPharma Inc. (NASDAQ:ARRY) - Beacon Chronicle
06/16/16 07:18 AMArray BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : June 16, 2016 -
06/16/16 04:16 AMEye Catching Stock: Array BioPharma Inc. (NASDAQ:ARRY) - News Oracle
06/15/16 02:39 PMPreview of Analysts Recommendation: Celgene Corporation (NASDAQ:CELG) , Array BioPharma Inc. (NASDAQ:ARRY) - Street Updates
06/15/16 07:22 AMHC Stocks in Hub: Array Biopharma Inc (NASDAQ:ARRY), Sarepta Therapeutics Inc (NASDAQ:SRPT) - share market updates (press release)
06/14/16 02:33 PMCan Array BioPharma Inc. (NASDAQ:ARRY) Surprise Analysts this Quarter? - Investor Newswire
06/14/16 07:44 AMHC Stocks Newsbeat: Array Biopharma Inc (NASDAQ:ARRY), HCA Holdings Inc (NYSE:HCA) - share market updates (press release)
06/14/16 07:44 AMAnalysts Rating Alert: Eli Lilly and Company (NYSE:LLY) , Array BioPharma Inc. (NASDAQ:ARRY) - Street Updates
06/14/16 07:44 AMStocks Earnings Review: Array BioPharma Inc. (NASDAQ:ARRY), Novartis AG (NYSE:NVS) - Beacon Chronicle
06/13/16 10:40 AMEarnings Expectations of the Stocks: Flowers Foods, Inc. (NYSE:FLO), Array BioPharma Inc. (NASDAQ:ARRY) - Beacon Chronicle
06/13/16 10:40 AMHC Stocks to Path: Intrexon Corp (NYSE:XON), Array Biopharma Inc (NASDAQ:ARRY) - share market updates (press release)
06/10/16 11:00 AMSunTrust Robinson Humphrey Initiates Coverage on Array Biopharma Inc to Buy - Trade Calls
06/09/16 11:28 AMEarnings Trends of the Stocks: Equity Residential (NYSE:EQR), Array BioPharma Inc. (NASDAQ:ARRY) - Beacon Chronicle
06/09/16 11:28 AMCan Array BioPharma Inc. (NASDAQ:ARRY) Meet Analysts Expectations? - Stocks Daily
06/09/16 11:28 AMArray BioPharma Inc. (NasdaqGM:ARRY) Fundamental Star Rating Report - CML News
06/09/16 09:27 AMHere's Why Array Biopharma Inc. Gained 18.1% in May -
06/08/16 03:00 PMSummary of Analyst's Study: LDR Holding Corporation (NASDAQ:LDRH) , Array BioPharma Inc. (NASDAQ:ARRY) - Street Updates
06/08/16 03:00 PMPrice Target Estimates: Array BioPharma Inc. (NASDAQ:ARRY) - News Oracle
06/08/16 03:00 PMAll You Need To Know About Array Biopharma Inc's (NASDAQ:ARRY) Upcoming NDA Submission - Market Exclusive
06/08/16 11:02 AMHC Stocks Momentum: Bristol-Myers Squibb Co (NYSE:BMY), Array Biopharma Inc (NASDAQ:ARRY) - share market updates (press release)
06/08/16 11:02 AMAnalysts Offer Insights on Healthcare Companies: Array Biopharma Inc. (NASDAQ: ARRY), Celgene Corporation ... - Analyst Ratings
06/08/16 11:02 AMEarnings Analysis to see: Array BioPharma Inc. (NASDAQ:ARRY), AstraZeneca PLC (NYSE:AZN) - Beacon Chronicle
06/08/16 09:10 AMAll You Need To Know About Array Biopharma Inc (ARRY)’s Upcoming NDA Submission -
06/07/16 08:09 PMSmall Cap Volatile Stocks: Array BioPharma Inc. (NASDAQ:ARRY), Immunomedics Inc. (NASDAQ:IMMU), Baytex ... - KC Register
06/07/16 02:37 PMArray BioPharma, Inc. (NASDAQ:ARRY) Reveals Binimetinib Phase 3 Study Results - Journal Transcript
06/07/16 10:36 AMArray Biopharma Inc (NASDAQ:ARRY) & Allergan plc Ordinary Shares (NYSE:AGN) Trending Healthcare Stocks - Wall Street 24
06/07/16 10:36 AMHC Stocks Zone: AbbVie Inc (NYSE:ABBV), Array Biopharma Inc (NASDAQ:ARRY) - share market updates (press release)
06/06/16 07:50 PMARRAY BIOPHARMA INC. (NASDAQ:ARRY) Financial Condition Compared to S&P 500 - CML News
06/06/16 01:48 PMArray Presents Full Results from Phase 3 NEMO Study - [at noodls] - BOULDER, Colo., June 6, 2016 /PRNewswire/ -- Array BioPharma (Nasdaq: ARRY) announced full results at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract No. 9500) ...
06/06/16 12:09 PMEarnings Estimates Highlight: DR Horton Inc. (NYSE:DHI), Array BioPharma Inc. (NASDAQ:ARRY) - Beacon Chronicle
06/06/16 12:09 PMAnalyst's Overview of Two Stocks: Novavax, Inc. (NASDAQ:NVAX) , Array BioPharma Inc. (NASDAQ:ARRY) - Street Updates
06/06/16 12:09 PMHC Stocks News Bulletin: Horizon Pharma PLC (NASDAQ:HZNP), Array Biopharma Inc (NASDAQ:ARRY) - share market updates (press release)
06/06/16 12:08 PMIs it Finally Safe to Buy Array BioPharma Inc (NASDAQ:ARRY)? - Street Report
06/04/16 11:02 AMArray BioPharma Inc. (ARRY) is Trading Higher on Unusual Volume for June 02 - Equities.com
06/04/16 08:08 AMEncorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal Cancer Compared to Historical Benchmarks - [at noodls] - BOULDER, Colo., June 4, 2016 /PRNewswire/ -- Array BioPharma (Nasdaq: ARRY) announced today updated results from a Phase 2 study of the combination of encorafenib and cetuximab, with or without alpelisib, ...
06/04/16 08:08 AMArray BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial - [at noodls] - BOULDER, Colo., June 4, 2016 /PRNewswire/ -- Array BioPharma (Nasdaq: ARRY), Pierre Fabre and Merck KGaA, Darmstadt, Germany, today jointly initiated the BEACON CRC (Binimetinib, Encorafenib And Cetuximab ...
06/04/16 08:08 AMMerck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant mCRC Phase III Trial - [at noodls] - 9a90ac7c-1236-4ee6-bd59-791e6a7a0881.pdf News Release Your Contact Gangolf Schrimpf +49 151 1454 9591 Not intended for UK- or US-based media June 4, 2016 BEACON CRC trial will assess efficacy of... This ...
06/03/16 08:39 PMArray BioPharma Inc. (NASDAQ:ARRY) Stock Update & Estimates - Stock Tick Tock
About Array Biopharma

Array Biopharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Company's wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARRY
  • CUSIP: 04269X10
Key Metrics:
  • Previous Close: $3.58
  • 50 Day Moving Average: $3.33
  • 200 Day Moving Average: $3.25
  • P/E Ratio: N/A
  • P/E Growth: -0.58
  • Market Cap: $494.86M
  • Current Quarter EPS Consensus Estimate: $-0.62 EPS
Additional Links:
Array Biopharma (NASDAQ:ARRY) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha